Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;188(6):885-892.
doi: 10.1007/s11046-023-00754-w. Epub 2023 Jun 14.

Epidemiology of Invasive Candidiasis in Patients with Hematologic Malignancy on Antifungal Prophylaxis

Margaret E McCort  1 , Helen Tsai  2
Affiliations
Review

Epidemiology of Invasive Candidiasis in Patients with Hematologic Malignancy on Antifungal Prophylaxis

Margaret E McCort et al. Mycopathologia. 2023 Dec.

Abstract

The landscape of invasive Candida infections in patients with hematologic malignancy has evolved due to the adoption of anti-fungal prophylaxis, advances in oncological therapies, and developments in antifungal therapies and diagnostics. Despite these scientific gains, the morbidity and mortality caused by these infections remain unchanged, highlighting the importance of an updated understanding of its epidemiology. Non-albicans Candida species are now the predominant cause of invasive candidiasis in patients with hematological malignancy. This epidemiological shift from Candida albicans to non-albicans Candida species is partially a consequence of selective pressure from extensive azole use. Further analysis of this trend suggests other contributing factors including immunocompromise caused by the underlying hematologic malignancy and the intensity of its associated treatments, oncological practices, and regional or institution specific variables. This review characterizes the changing distribution of Candida species in patients with hematologic malignancy, describes the causes driving this change, and discusses clinical considerations to optimize management in this high-risk patient population.

Keywords: Antifungal; Candidemia; Hematologic malignancy; Hematopoietic stem cell transplant; Non-albicans Candida.

PubMed Disclaimer

References

    1. Centers for Disease Control and Prevention. Hematologic Cancer Incidence, Survival, and Prevalence. USCS Data Brief, no. 30. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022.
    1. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with haematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52. https://doi.org/10.1002/cncr.24507 . - DOI - PubMed
    1. Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective cohort multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7. https://doi.org/10.1111/1469-0691.12312 . - DOI - PubMed
    1. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R, et al. Increase in C krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;326:1274–7. https://doi.org/10.1111/1469-0691.12312 . - DOI
    1. Pasqualotto AC, Rosa DD, Medeiros LR, Severo LC. Candidemia and cancer: patients are not all the same. BMC Infect Dis. 2006;6:1–7. https://doi.org/10.1186/1471-2334-6-50 . - DOI

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources